Investor Update
Filed with ASX · · 29 pages · English
On 6ix: 6ix.com/news/investor-update-58
The Company remains well positioned for the launch of Detach™, its non-antibiotic treatment for gastrointestinal disease. Initially focused on pigs, launch is expected in 2017 and follows the Anatara’s application in October to the Australian Pesticides and Veterinary Medicines Authority (APVMA) for approval to sell and market Detach™. Chairman and CEO, Dr Mel Bridges commented, “With our APVMA su
Anatara Lifesciences Ltd on 6ix
Earlier from Anatara Lifesciences
- R&D Tax Refund
- APVMA Submission Major Milestone Achieved
- Successful Completion of Target Safety Study
- Anatara Expands Executive Team
- Anatara Trial Update
Later from Anatara Lifesciences
- Zoetis Second Payment is received
- Investor Update and R&D Tax Rebate
- ANR and Zoetis to negotiate International Detach Commercial
- Preliminary Final Report
- Pork CRC Options extended by 12 Months
Follow Anatara Lifesciences into a list and get an email when it puts out news.
Follow Anatara Lifesciences